Previous Close | 4.8000 |
Open | 0.2300 |
Bid | 8.8500 |
Ask | 10.4000 |
Strike | 5.50 |
Expire Date | 2024-06-14 |
Day's Range | 0.2300 - 4.8000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.